<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190726044337N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-10-20</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Tecar Therapy on Peripheral Neuropathy in Patients with Type II Diabetes</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the Effectiveness of Infrared radiation and Tecar Therapy with Infrared radiation on Peripheral Neuropathy  in Patients with Type II Diabetes</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-04-08</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>24</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/41280</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple Randomization: Patients were assigned a number according to the order of selection and were divided into treatment and control groups by sortition. The first pulled out number was assigned to the treatment group and the subsequent numbers were assigned to the two groups, respectively, Blinding description: Only the Participants of the Study were Blinded and did not know which of the two treatment and control groups were assigned to them.That way, the Individuals in both groups were treated on separate days.</study_design>
      <phase>3</phase>
      <hc_freetext>Type II Diabetes.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients in this group are treated with Infrared radiation (electromagnetic fields with 890 nanometers ,70-80 centimeters away from the surfaces of the foot) for 60 minutes and Capacitive Tecar Therapy (electromagnetic fields with 300-800 Kilohertz and intensity less than 50%) on Tibial nerve pathway with for 20 minutes in each session.Infrared radiation treatment is applied to dorsal, plantar, medial and lateral surface of the feet for twenty minutes and then, the passive electrode of tecar device is placed anterior surface of legs and its active electrode is moved along the tibial nerve pathway for twenty minutes in prone position. Intervention 2: Control group: Patients in this group are treated with Infrared radiation (electromagnetic fields with 890 nanometers , 70-80 centimeters away from the surfaces of the foot) for 60 minutes and Sham Capacitive Tecar Therapy (electromagnetic fields with 300-800 Kilohertz and  Zero intensity ) on Tibial nerve pathway with for 20 minutes in each session.Infrared radiation treatment is applied to dorsal, plantar, medial and lateral surface of the feet for twenty minutes and then, the passive electrode of tecar device is placed anterior surface of legs and its active electrode is moved along the tibial nerve pathway for twenty minutes in prone position; except that the current intensity is zero.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No More Information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Niajalili</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 9, Kheyri Alley, Sardar-e Jangal Ave</address>
        <city>lahijan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4418786769</zip>
        <telephone>+98 13 4222 4593</telephone>
        <email>Maryam_Niajalili@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Asghar Rezasoltani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Rehabilitation Shahid Beheshti University of Medical Science, Damavand Ave, Emam Hossein Sq</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1616913111</zip>
        <telephone>009877561721</telephone>
        <email>A_rezasoltani@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age: 18-75
The least duration of illness affliction was more than six months
Patients have type II diabetes Mellitus with signs and Symtoms of mild(I) to moderate(II) Peripheral Neuropathy
Pain Intensity which was based on VAS (Visual Analog Scale) scores were more than three</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy
Diabetic Infectious Wound
Involvement of Cardiovascular system
Involvement of Respiratory system
To have Pace maker</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E11.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Type 2 diabetes mellitus with neurological complications</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients in this group are treated with Infrared radiation (electromagnetic fields with 890 nanometers ,70-80 centimeters away from the surfaces of the foot) for 60 minutes and Capacitive Tecar Therapy (electromagnetic fields with 300-800 Kilohertz and intensity less than 50%) on Tibial nerve pathway with for 20 minutes in each session.Infrared radiation treatment is applied to dorsal, plantar, medial and lateral surface of the feet for twenty minutes and then, the passive electrode of tecar device is placed anterior surface of legs and its active electrode is moved along the tibial nerve pathway for twenty minutes in prone position.</i_keyword>
      <i_keyword>Control group: Patients in this group are treated with Infrared radiation (electromagnetic fields with 890 nanometers , 70-80 centimeters away from the surfaces of the foot) for 60 minutes and Sham Capacitive Tecar Therapy (electromagnetic fields with 300-800 Kilohertz and  Zero intensity ) on Tibial nerve pathway with for 20 minutes in each session.Infrared radiation treatment is applied to dorsal, plantar, medial and lateral surface of the feet for twenty minutes and then, the passive electrode of tecar device is placed anterior surface of legs and its active electrode is moved along the tibial nerve pathway for twenty minutes in prone position; except that the current intensity is zero.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Intensity of pain. Timepoint: Before treatment, after ten session, Follow up for six weeks. Method of measurement: Base on visual analogue scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Tactile sensation of feet. Timepoint: Before treatment, After ten session, Follow up for six weeks. Method of measurement: Monofilament 5.07/10 g.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-12-18</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>3th Floor, Medical school, Next to the Taleghani Hospital, Evin, Shahid Chamran Highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
